Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations

Graham, J., Earnshaw, S., Lim, J., Luthra, R., & Borker, R. (2016). Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations. Journal of Clinical Pathways, 2(4), 31-39. http://www.journalofclinicalpathways.com/article/cost-effectiveness-afatinib-versus-erlotinib-first-line-treatment-patients-metastatic-non